ClinicalTrials.Veeva

Find clinical trials for Ovarian Cancer in Sevilla, AN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Sevilla, AN, ESP:

ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

chemotherapy and in maintenance, in patients presenting epithelial ovarian cancer (including patients with primary peritoneal and /...

Active, not recruiting
Ovarian Cancer
Drug: placebo + avastin + platinum-based chemotherapy
Drug: atezolizumab + avastin + platinum-based chemotherapy

Phase 3

ARCAGY/ GINECO GROUP

Sevilla, Spain and 74 other locations

Locations recently updated

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer...

Enrolling
Chemotherapy-induced Thrombocytopenia
Drug: Romiplostim
Drug: Placebo

Phase 3

Amgen
Amgen

Sevilla, Andalucía, Spain and 119 other locations

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

placebo plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or primary peritoneal cancer with 1s...

Active, not recruiting
Recurrent Ovarian Carcinoma
Drug: Bevacizumab
Drug: Chemotherapy

Phase 3

AGO Research

Jerez De La Frontera, Spain and 110 other locations

Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)

of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with hig...

Active, not recruiting
Peritoneal Cancer
Fallopian Tube Cancer
Drug: Mirvetuximab soravtansine

Phase 2

ImmunoGen
ImmunoGen

Sevilla, Spain and 77 other locations

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL)

in patients with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, wh...

Active, not recruiting
Epithelial Ovarian Cancer
Peritoneal Cancer
Drug: Paclitaxel
Drug: Pegylated liposomal doxorubicin

Phase 3

ImmunoGen
ImmunoGen

Sevilla, Spain and 207 other locations

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

This study aims to assess efficacy of Niraparib (GSK3985771) as maintenance treatment in participants with Stage III or IV ovarian cancer...

Active, not recruiting
Ovarian Neoplasms
Drug: Placebo
Drug: Niraparib

Phase 3

Tesaro
Tesaro

Sevilla, Spain and 194 other locations

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based...

Active, not recruiting
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Drug: Rucaparib
Drug: Placebo Oral Tablet

Phase 3

pharmaand

Sevilla, Spain and 237 other locations

Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA)

Atezolizumab in this study is expected to have a positive benefit-risk profile for the treatment of patients with platinum-sensitive relapse of ovarian...

Active, not recruiting
Recurrent Ovarian Carcinoma
Drug: Niraparib
Drug: Atezolizumab

Phase 3

Grupo Español de Investigación en Cáncer de Ovario

Sevilla, Spain and 70 other locations

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

indications include endometrial, esophageal, esophagogastric junction (EGJ), gastric, head and neck, melanoma, non-small cell lung (NSCLC), ovarian...

Enrolling
Endometrial Cancer
Esophageal Cancer
Genetic: Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks

Phase 1

Adaptimmune

Sevilla, Spain and 21 other locations

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary perito...

Active, not recruiting
Fallopian Tube Cancer
Ovarian Cancer
Biological: Pembrolizumab
Drug: Paclitaxel

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Sevilla, Spain and 226 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems